Proteimax is a small biotech company established in 2001 to create an innovation supply chain for the biopharmaceutical industry. Proteimax developed a young and dynamic technology, with a successful team of deep knowledge and experience in finding novel peptide-based therapeutic molecules. The company already has four new peptide based drugs with exciting results, both in vitro and in vivo. The potential clinical application for Proteimax novel molecules includes diabetes, obesity, chronic pain, neurological diseases and cancer.


Click here to go back to see other startups.